Quantcast

Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr Instagram
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
December 19, 2014, 09:28:40 AM

Login with username, password and session length


Members
Stats
  • Total Posts: 649867
  • Total Topics: 49600
  • Online Today: 187
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Huge weak spot found on HIV in Scripps-led study  (Read 1352 times)

0 Members and 1 Guest are viewing this topic.

Offline Tadeys

  • Member
  • Posts: 162
Huge weak spot found on HIV in Scripps-led study
« on: May 26, 2013, 07:18:29 PM »
LA JOLLA — A weak spot on the surface of HIV-1, the most prevalent AIDS virus, is far larger than originally thought, according to a study led by scientists at The Scripps Research Institute.

This “supersite of immune vulnerability” may be helpful in developing an AIDS vaccine, said the study published Sunday in Nature Structural & Molecular Biology. Its first author is Leopold Kong and senior author is Ian A. Wilson, both of Scripps.

Much of HIV’s surface mutates rapidly, escaping the body’s immune system and also vaccines. But certain regions of the surface required for infection can’t mutate much. These areas can be targeted by antibodies that neutralize a broad range of HIV strains.

Wilson and colleagues have searched for years for these broadly neutralizing antibodies, which they plan to use as a template for a vaccine. The newly discovered weak region provides a good target for producing even more of the broadly neutralizing antibodies, the paper said.

The paper “tracks a course for the next critical step in vaccine design,” said infectious disease researcher Robert C. Liddington of the Sanford-Burnham Medical Research Institute, who was not involved in the study. Liddington’s research includes broadly neutralizing antibodies, for HIV and influenza, another highly mutable virus.

Producing a so-called universal flu vaccine that protects against the great majority of strains requires some of the same technology needed for an HIV vaccine. Wilson and his colleagues are researching a universal flu vaccine in a partnership with Janssen Pharmaceuticals, a division of Johnson & Johnson.

The vulnerable region occurs on a part of the HIV shell called gp120, used by the virus to attach to cells it infects. Because it performs an essential function, mutations on gp120 are constrained. That appears to make the region an ideal vaccine target.

However, researchers have been unsuccessful in making an effective vaccine from gp120. A 2006 study led by Scripps researcher Dennis Burton found that the vulnerable regions are concealed from the immune system.

The new study found that a portion of gp120 thought to be narrowly accessible to antibodies is much more widely open than previously believed. The region allows antibodies to bind in several different locations and at multiple angles of attachment.

“Now that scientists understand how these special antibodies work, there is real optimism that the next crucial step can be achieved: the synthesis of fragments of gp120 that could act as the major element of a universal vaccine,” Liddington said.

Broadly neutralizing HIV antibodies were originally discovered in some HIV-positive people. But it usually takes two to three years after infection before they’re produced, the paper said. By then, the virus is firmly established.

A vaccine that produces broadly neutralizing antibodies in the uninfected might be able to block HIV before it gets a foothold, the study said. It said the most promising approach could be to put the various antibody-provoking regions, called epitopes, on microscopic scaffolds that prominently display them so the immune system can recognize them.

The study was funded in part under a $77 million, seven-year grant awarded last July by the National Institutes of Health. The grant established the Center for HIV/AIDS Vaccine Immunology & Immunogen Discovery, or CHAVI-ID, at Scripps.

Other sources include the International AIDS Vaccine Initiative Neutralizing Antibody, or IAVI, Center, also located at Scripps and the HIV Vaccine Research and Design program.

http://www.utsandiego.com/news/2013/may/26/hiv-neutralizing-gp120/




Offline sensual1973

  • Member
  • Posts: 196
Re: Huge weak spot found on HIV in Scripps-led study
« Reply #1 on: May 27, 2013, 07:20:22 AM »
ok.
God grant me the serenity to accept the things i can not change.

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.